Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open. 2016; 1(6):e000118.